16
Participants
Start Date
February 23, 2024
Primary Completion Date
February 23, 2029
Study Completion Date
February 23, 2044
CD33KO-HSPC; CART33
"CD33KO-HSPC: Stem cell transplant (also known as bone marrow transplant) is a common treatment used for patients with blood cancers, but for this transplant we will first modify the cells, in order to make the CAR T-cell treatment safer for when the patient receives them later. The modification is a type of gene editing - this means changing the DNA of the cells, so that a protein that the bone marrow stem cells usually show on their surface is not shown any more. This makes the bone marrow cells invisible to the CAR T-cells, and makes this therapy safer for the patient. The protein is called CD33.~CART33: Chimeric Antigen Receptor T-cells (CART) are immune cells which are modified by adding a CAR molecule, which makes them much more efficient at finding and killing cancer cells. In this case, the CAR T-cells are programmed to target a protein called CD33, which is found on the surface of leukemia cells, and on healthy bone marrow cells."
RECRUITING
University of Pennsylvania, Philadelphia
University of Pennsylvania
OTHER